• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

超立方体用于识别囊性纤维化肺病快速进展的地理标记物。

Hypercubes to identify geomarkers of rapid cystic fibrosis lung disease progression.

作者信息

Cheng Yizi, Brokamp Cole, Manning Erika Rasnick, Kramer Elizabeth L, Ryan Patrick H, Szczesniak Rhonda D, Gecili Emrah

机构信息

Division of Biostatistics & Epidemiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave (MLC 5041), Cincinnati, OH, 45229, USA.

Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA.

出版信息

BMC Med Inform Decis Mak. 2025 Aug 13;25(1):304. doi: 10.1186/s12911-025-03097-2.

DOI:10.1186/s12911-025-03097-2
PMID:40804631
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12344988/
Abstract

BACKGROUND

Prior research has shown that place-based environmental exposures and community characteristics, known as geomarkers, are associated with accelerated lung function decline and increased mortality in individuals with cystic fibrosis (CF). Although geomarkers have been linked to pulmonary outcomes in other respiratory diseases, it is unknown which have the greatest predictive power for rapid lung function decline in CF.

METHODS

We adapted an existing statistical procedure, which arranges candidate variables in a k-dimensional hypercube, where the hypercube forms a set of variables for a multi-stage selection process involving complex longitudinal data. We embedded the hypercube within a dynamic prediction model of rapid lung function decline, in order to accommodate complexity in lung function trajectories. This practical approach simultaneously selects a handful of genuinely predictive markers among candidates and accounts for complex correlations in longitudinal marker data. Our method is applied to actual geomarker and lung-function outcomes data from the existing Cystic Fibrosis Patient Registry and Cincinnati Cystic Fibrosis Center datasets.

RESULTS

We applied a 4 × 4 × 4 3-D hypercube to the national and local datasets and selected a subset of geomarkers using p-values from testing coefficients of the association between each geomarker and lung function decline in the dynamic prediction model. Based on the national data analyses, some road density-related geomarkers were selected, including some air pollution-related and greenspace-related variables. Simulations showed the proposed method's variable selection efficacy and robust performance in identifying true predictors, particularly under weak correlation (ρ≤0.6), although performance dipped with stronger correlations (ρ=0.9).

CONCLUSIONS

The proposed method is a useful approach for selecting a small set of truly relevant demographic, clinical, and place-based predictors of rapid lung function decline while accounting for the complex correlations inherent in longitudinal lung-function data. We found that selection results differed according to spatial resolution of the geomarkers. Our findings have potential to improve care decisions for people with CF.

摘要

背景

先前的研究表明,基于地点的环境暴露和社区特征(即地理标志物)与囊性纤维化(CF)患者的肺功能加速下降和死亡率增加有关。尽管地理标志物已与其他呼吸系统疾病的肺部结局相关联,但对于CF患者肺功能快速下降而言,哪些地理标志物具有最大的预测能力尚不清楚。

方法

我们采用了一种现有的统计程序,该程序将候选变量排列在一个k维超立方体内,其中超立方体形成了一组变量,用于涉及复杂纵向数据的多阶段选择过程。我们将超立方体嵌入到肺功能快速下降的动态预测模型中,以适应肺功能轨迹的复杂性。这种实用方法同时在候选标志物中选择少数真正具有预测性的标志物,并考虑纵向标志物数据中的复杂相关性。我们的方法应用于来自现有囊性纤维化患者登记处和辛辛那提囊性纤维化中心数据集的实际地理标志物和肺功能结局数据。

结果

我们将一个4×4×4的三维超立方体应用于国家和本地数据集,并使用动态预测模型中每个地理标志物与肺功能下降之间关联的测试系数的p值来选择地理标志物的一个子集。基于国家数据分析,选择了一些与道路密度相关的地理标志物,包括一些与空气污染和绿地相关的变量。模拟显示了所提出方法在识别真正预测因子方面的变量选择功效和稳健性能,特别是在弱相关性(ρ≤0.6)情况下,尽管在强相关性(ρ=0.9)时性能有所下降。

结论

所提出的方法是一种有用的方法,可用于选择一小部分真正相关的人口统计学、临床和基于地点的预测因子,以预测肺功能快速下降,同时考虑纵向肺功能数据中固有的复杂相关性。我们发现选择结果因地理标志物的空间分辨率而异。我们的研究结果有可能改善CF患者的护理决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c8/12344988/916f0350ea77/12911_2025_3097_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c8/12344988/013cd5d27ca2/12911_2025_3097_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c8/12344988/31cba37bfb2f/12911_2025_3097_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c8/12344988/dbd82faada48/12911_2025_3097_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c8/12344988/2dd1e3c16086/12911_2025_3097_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c8/12344988/52d17af1b16d/12911_2025_3097_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c8/12344988/916f0350ea77/12911_2025_3097_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c8/12344988/013cd5d27ca2/12911_2025_3097_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c8/12344988/31cba37bfb2f/12911_2025_3097_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c8/12344988/dbd82faada48/12911_2025_3097_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c8/12344988/2dd1e3c16086/12911_2025_3097_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c8/12344988/52d17af1b16d/12911_2025_3097_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c8/12344988/916f0350ea77/12911_2025_3097_Fig6_HTML.jpg

相似文献

1
Hypercubes to identify geomarkers of rapid cystic fibrosis lung disease progression.超立方体用于识别囊性纤维化肺病快速进展的地理标记物。
BMC Med Inform Decis Mak. 2025 Aug 13;25(1):304. doi: 10.1186/s12911-025-03097-2.
2
Antibiotic treatment for non-tuberculous mycobacteria lung infection in people with cystic fibrosis.囊性纤维化患者非结核分枝杆菌肺部感染的抗生素治疗
Cochrane Database Syst Rev. 2025 Mar 27;3(3):CD016039. doi: 10.1002/14651858.CD016039.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Inhaled mannitol for cystic fibrosis.吸入用甘露醇治疗囊性纤维化。
Cochrane Database Syst Rev. 2018 Feb 9;2(2):CD008649. doi: 10.1002/14651858.CD008649.pub3.
5
Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis.气道清除技术与囊性纤维化的非气道清除技术比较。
Cochrane Database Syst Rev. 2023 Apr 12;4(4):CD001401. doi: 10.1002/14651858.CD001401.pub4.
6
Non-invasive ventilation for cystic fibrosis.囊性纤维化的无创通气
Cochrane Database Syst Rev. 2017 Feb 20;2(2):CD002769. doi: 10.1002/14651858.CD002769.pub5.
7
Exercise versus airway clearance techniques for people with cystic fibrosis.运动与气道廓清技术治疗囊性纤维化。
Cochrane Database Syst Rev. 2022 Jun 22;6(6):CD013285. doi: 10.1002/14651858.CD013285.pub2.
8
Macrolide antibiotics (including azithromycin) for cystic fibrosis.大环内酯类抗生素(包括阿奇霉素)治疗囊性纤维化。
Cochrane Database Syst Rev. 2024 Feb 27;2(2):CD002203. doi: 10.1002/14651858.CD002203.pub5.
9
Inhaled mannitol for cystic fibrosis.吸入用甘露醇治疗囊性纤维化。
Cochrane Database Syst Rev. 2015 Oct 9(10):CD008649. doi: 10.1002/14651858.CD008649.pub2.
10
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.

本文引用的文献

1
Social-environmental phenotypes of rapid cystic fibrosis lung disease progression in adolescents and young adults living in the United States.美国青少年和青年中囊性纤维化肺病快速进展的社会环境表型
Environ Adv. 2023 Dec;14. doi: 10.1016/j.envadv.2023.100449. Epub 2023 Nov 10.
2
Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical Interpretations.肺功能在囊性纤维化中的下降:数据可用性和建模策略对临床解释的影响。
Ann Am Thorac Soc. 2023 Jul;20(7):958-968. doi: 10.1513/AnnalsATS.202209-829OC.
3
Built environment factors predictive of early rapid lung function decline in cystic fibrosis.
与囊性纤维化患者早期肺功能快速下降相关的建筑环境因素。
Pediatr Pulmonol. 2023 May;58(5):1501-1513. doi: 10.1002/ppul.26352. Epub 2023 Feb 21.
4
A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators.一项调查:了解未受益于 CFTR 调节剂的 CF 患者的健康状况和观点。
Pediatr Pulmonol. 2022 May;57(5):1253-1261. doi: 10.1002/ppul.25859. Epub 2022 Mar 28.
5
Seasonal variation of lung function in cystic fibrosis: longitudinal modeling to compare a Midwest US cohort to international populations.囊性纤维化患者肺功能的季节性变化:纵向建模比较美国中西部队列与国际人群。
Sci Total Environ. 2021 Jul 1;776. doi: 10.1016/j.scitotenv.2021.145905. Epub 2021 Mar 1.
6
Bayesian regularization for a nonstationary Gaussian linear mixed effects model.贝叶斯正则化在非平稳高斯线性混合效应模型中的应用。
Stat Med. 2022 Feb 20;41(4):681-697. doi: 10.1002/sim.9279. Epub 2021 Dec 12.
7
An empirical comparison of segmented and stochastic linear mixed effects models to estimate rapid disease progression in longitudinal biomarker studies.在纵向生物标志物研究中,用于估计疾病快速进展的分段线性混合效应模型和随机线性混合效应模型的实证比较。
Stat Biopharm Res. 2021;13(3):270-279. doi: 10.1080/19466315.2020.1870546. Epub 2021 Feb 4.
8
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.依伐卡托/泰它卡托/艾氟卡托治疗囊性纤维化的临床疗效:一项临床试验。
Am J Respir Crit Care Med. 2022 Mar 1;205(5):529-539. doi: 10.1164/rccm.202108-1986OC.
9
Influences of environmental exposures on individuals living with cystic fibrosis.环境暴露对囊性纤维化患者的影响。
Expert Rev Respir Med. 2020 Jul;14(7):737-748. doi: 10.1080/17476348.2020.1753507. Epub 2020 Apr 26.
10
Dynamic predictive probabilities to monitor rapid cystic fibrosis disease progression.动态预测概率监测囊性纤维化疾病的快速进展。
Stat Med. 2020 Mar 15;39(6):740-756. doi: 10.1002/sim.8443. Epub 2019 Dec 9.